SPRY · XBRL financial data

ARS Pharmaceuticals financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SPRY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	5,506	1,316	30	89,149	84,278
Cost of goods and services sold	—	—	0	—	—
Research and development	61,501	18,376	20,266	19,580	13,181
Selling, general and administrative	—	603	940	71,675	230,122
General and administrative	28,083	18,456	47,284	—	—
Total operating expenses	89,584	36,832	67,550	92,232	263,726
Operating income (loss)	(89,584)	(35,516)	(67,520)	(3,083)	(179,448)
Other income (expense)	(789)	974	13,155	11,369	8,070
Income tax expense (benefit)	0	0	0	288	(80)
Net income (loss)	(89,478)	(34,682)	(54,365)	7,998	(171,298)
Earnings per share, basic USD per share	(0.70)	(0.87)	(0.57)	0.08	(1.74)
Earnings per share, diluted USD per share	(0.70)	(0.87)	(0.57)	0.08	(1.74)
Weighted average shares, basic thousands of shares	28,872	39,956	95,215	96,937	98,566
Weighted average shares, diluted thousands of shares	28,872	39,956	95,215	102,391	98,566

Fiscal years (SPRY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	254,045	210,518	70,971	50,817	41,317
Short-term investments	0	63,863	157,389	263,205	203,669
Accounts receivable	—	—	0	8,175	25,347
Inventory	—	—	0	5,212	31,422
Prepaid and other current assets	7,447	3,319	3,366	6,886	6,194
Total current assets	261,492	277,700	231,726	334,295	284,896
Property and equipment, net	2,212	329	574	1,029	2,465
Right-of-use asset	4,733	445	250	37	—
Total assets	333,467	281,435	233,188	351,153	327,652
Accounts payable	2,078	1,659	759	9,870	5,725
Accrued liabilities	11,727	—	—	—	—
Total current liabilities	14,892	5,444	2,391	23,440	39,145
Lease liability, non-current	4,760	251	37	0	—
Total liabilities	19,652	8,549	2,428	94,355	213,394
Accumulated deficit	(186,212)	(76,938)	(131,303)	(123,305)	(294,603)
Total stockholders' equity	313,815	272,886	230,760	256,798	114,258
Total liabilities and equity	333,467	281,435	233,188	351,153	327,652
Common shares outstanding (cover page) thousands of shares	35,143	94,403	96,502	98,120	99,297

Fiscal years (SPRY's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(89,478)	(34,682)	(54,365)	7,998	(171,298)
Stock-based compensation	19,187	5,843	9,235	14,534	22,095
Net cash from operating activities	(66,760)	(40,078)	(59,266)	13,548	(170,866)
Purchases of property and equipment	1,372	199	175	563	339
Net cash from investing activities	(66,478)	(199)	(87,180)	(106,101)	56,768
Net cash from financing activities	614	190,732	6,899	72,399	104,598
Net change in cash	35,542	150,455	(139,547)	(20,154)	(9,500)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ARS Pharmaceuticals	25,621	37,710	(33,713)*	100.5M	3.0 quarters	Q3 FY26 10-QSep 30, 2026
Spyre Therapeutics	82,727	not reported	(77,495)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Schrodinger	246,983	64,491	(47,578)*	not reported	10.9 quarters	Q3 FY26 10-QSep 30, 2026
Mannkind	41,276	101,870	(34,549)*	321.6M	4.2 quarters	Q3 FY26 10-QSep 30, 2026
Novavax	222,455	68,298	(94,242)*	165.0M	9.4 quarters	Q3 FY26 10-QSep 30, 2026
Harrow	83,889	70,661	(9,755)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	45,792	83,699	46,367*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172,000	222,800	12,900	218.3M	—	Q1 FY27 10-QAug 31, 2026
Innoviva	581,394	106,120	41,698*	71.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 11:33 PM ET. The filing on SEC.gov is the record.